Please login to the form below

Not currently logged in
Email:
Password:

polycystic kidney disease

This page shows the latest polycystic kidney disease news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Daily Brief: Cellectis gains Novartis scientist, EU label updates for Janssen and Otsuka

Otsuka gains European nod for Jinarc extension. The European Commission has approved a label extension for Jinarc (tolvaptan) to include adult patients with CKD stage 4 Autosomal Dominant Polycystic Kidney Disease ... Jinarc is the only drug treatment

Latest news

More from news
Approximately 2 fully matching, plus 11 partially matching documents found.

Latest from PMHub

  • Making good practice common practice in rare disease

    However, fatigue scores can’t be explained purely by disease activity and depression. ... 2015 - 88% of people with early-stage autosomal dominant polycystic kidney disease (ADPKD), reported physical symptoms including pain and general malaise.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

The relevance of patient perspectives to value
Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?
Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...
real world studies
The evolution of real-world studies
How industry and regulators are using real-world data...

Infographics